Nature’s Care finally clinches sale to China

Chinese state-owned enterprises’ acquisition of Australia’s third-largest vitamins firm by sales reflects the country’s hunger for food safety – but not at any price.
April 11, 2018

Chinese conglomerate Citic Ltd is clubbing together with a unit of sovereign wealth fund China Investment Corporation and others to buy Australia Nature’s Care Biotech for less than A$800 million ($620 million), according to people familiar with the deal.

¬ Haymarket Media Limited. All rights reserved.

Sign in to read on!

Registered users get 2 free articles in 30 days.

Subscribers have full unlimited access to FinanceAsia.

Not signed up? New users get 2 free articles per month, plus a 7-day unlimited free trial.

Questions?
See here for more information on licences and prices, or contact [email protected].

Related Articles

Food safety sharpens China’s appetite for M&A

China’s drive to improve food safety via foreign acquisitions faces growing anti-trust barriers and management failures. FinanceAsia talks to deal-makers about how to make the recipe just right.
February 13, 2017

Biostime swallows Aussie vitamin maker for $992m

The Chinese baby formula maker's deal for Australia's Swisse Wellness shows SOEs have rivals for overseas M&A targets. But some wonder if Biostime is punching above its weight.
September 19, 2015

CIC, INA and SOFAZ team up for China–Asean investments

The Galaxy Orientis fund has raised $520m out of a $1bn target from China Investment Corporation, Indonesia Investment Authority and State Oil Fund of the Republic of Azerbaijan. The PE fund is eyeing investments across the Asean-China corridor.
April 19, 2026